Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

As an enterprise engaged in the development, manufacturing and commercialization of specialty plasma-derived therapeutics, ...

Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

The global generic oncology drugs market is set for consistent growth over the next decade, with sales anticipated to rise from USD 23,743.5 million in 2025 to USD 30,606.3 million by 2035, reflecting ...

The "43rd Annual JP Morgan Healthcare Conference, January 13-16, 2025" report has been added to ResearchAndMarkets.com's offering.The 43rd Annual JP Morgan Healthcare Conference took place in San ...

South Korean vaccine maker SK bioscience today revealed that it has received prior notification from the Pan American Health ...

Corneal Ulcer Treatment MarketThe global corneal ulcer treatment market is projected to grow at a CAGR of 5.2% from 2024 to 2034, reaching a market value of USD 1,601.1 million by 2034. In 2024, the ...

FDA recently announced new safety requirements for DPD screening in cancer patients. Kristine Ashcraft, founder and CEO of ...

Women's Health Therapeutics Market Rising Awareness and Government Initiatives Drive Growth AUSTIN, TX, UNITED STATES, February 28, 202 ...